Neurocrine Biosciences Inc. (NBIX)
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock
Neurocrine Biosciences posts standout Q3 beat as INGREZZA and CRENESSITY drive 28% product sales growth.
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $1.24 per share a year ago.
Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice
Does Neurocrine Biosciences (NBIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neurocrine Biosciences: Buy Rated As Q3 2025 Earnings Catalyst Approaches
Neurocrine Biosciences is rated BUY, driven by strong INGREZZA sales, Prenepsi growth, and a promising late-stage neuropsychiatry pipeline. NBIX's Q2 2025 revenue reached $682 million, with INGREZZA contributing 91% and Prenepsi expanding its rare-disease market presence. Robust cash reserves of $1.8 billion and disciplined expense management position NBIX to self-fund pipeline innovation and future product launches.
Neurocrine Biosciences, Inc. (NBIX) Presents At Cantor Global Healthcare Conference 2025 Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:00 PM EDT Company Participants Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Presentation Joshua Schimmer Biotech Equity Research Analyst Now we're ready to get started. All right.
Neurocrine Biosciences Positioned For Growth And New Potential Blockbusters
Neurocrine Biosciences' Ingrezza still generates most of its total revenues. This is their blockbuster drug. I also believe Ingrezza is well-positioned for future growth with new label additions, and IRA price protection warrants a bullish stance. Also, Crenessity's recent launch beat expectations, and the drug is key as a long-term second growth pillar.
Neurocrine Biosciences, Inc. (NBIX) Q2 2025 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants n - Corporate Participant Eiry Wyn Roberts - Corporate Participant Strategic Advisor - Corporate Participant Eric S. Benevich - Chief Commercial Officer Kyle W.
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $0.63 per share a year ago.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences: Still A Buy After 30% Uplift Since My Last Coverage
Neurocrine's core assets, INGREZZA and Crenessity, can drive strong revenue growth with robust patent protection and significant market underpenetration. The pharma's pipeline is advancing, with multiple late-stage studies in major depressive disorder and schizophrenia offering substantial upside if successful. Competition remains a risk, but INGREZZA and Crenessity face limited near-term threats; pipeline assets could add billions in value if data is positive.
